3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Neoplasm Metastasis
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Oligometastatic Prostate Carcinoma
1
Neoplasms by Site
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Fatigue
1
Depression
1
Cancer Pain
1
Advanced Prostate Cancer
1
Adenocarcinoma
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Abiraterone Acetate
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled